Cargando…

Appropriate composites of cefoperazone–sulbactam against multidrug-resistant organisms

OBJECTIVES: This study aims to assess the in vitro activity of different cefoperazone–sulbactam ratios against different multidrug-resistant organisms (MDROs). MATERIALS AND METHODS: Minimum inhibitory concentrations (MICs) and susceptibility rates of cefoperazone, sulbactam and cefoperazone–sulbact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lai, Chih-Cheng, Chen, Chi-Chung, Lu, Ying-Chen, Lin, Tsuey-Pin, Chuang, Yin-Ching, Tang, Hung-Jen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6138961/ https://www.ncbi.nlm.nih.gov/pubmed/30237728 http://dx.doi.org/10.2147/IDR.S175257

Ejemplares similares

In vitro activity of cefoperazone and cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa
por: Lai, Chih-Cheng, et al.
Publicado: (2018)

In Vitro Antimicrobial Activity of Various Cefoperazone/Sulbactam Products
por: Sheu, Ming-Jen, et al.
Publicado: (2020)

Optimal Dose of Cefoperazone-Sulbactam for Acute Bacterial Infection in Patients with Chronic Kidney Disease
por: Chao, Chien-Ming, et al.
Publicado: (2022)

The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia
por: Lai, Chih-Cheng, et al.
Publicado: (2023)

Hypersensitivity vasculitis induced by cefoperazone/sulbactam
por: Islek, Ismail, et al.
Publicado: (2003)

Cefoperazone-Sulbactam Associated Refractory Seizures
por: Chovatiya, Harshad, et al.
Publicado: (2021)

Cefoperazone/sulbactam-induced hemolytic anemia
por: Sun, XM, et al.
Publicado: (2023)

Clinical Efficacy of Cefoperazone-Sulbactam versus Piperacillin-Tazobactam in the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia
por: Chen, Chia-Hung, et al.
Publicado: (2021)

The Potential Role of Sulbactam and Cephalosporins Plus Daptomycin Against Daptomycin-Nonsusceptible VISA and H-VISA Isolates: An In Vitro Study
por: Lai, Chih-Cheng, et al.
Publicado: (2019)

Correlation Between Cefoperazone/Sulbactam MIC Values and Clinical Outcomes of Escherichia coli Bacteremia
por: Lin, Shang-Yi, et al.
Publicado: (2022)

Efficacy and safety of cefoperazone-sulbactam in empiric therapy for febrile neutropenia: A systemic review and meta-analysis
por: Lan, Shao-Huan, et al.
Publicado: (2020)

Polymyxin B, Cefoperazone Sodium-Sulbactam Sodium, and Tigecycline against Multidrug-Resistant Acinetobacter baumannii Pneumonia
por: Hu, Guangxue, et al.
Publicado: (2022)

Hemolytic Anemia and Reactive Thrombocytosis Associated With Cefoperazone/Sulbactam
por: Zhou, Ling, et al.
Publicado: (2019)

Comparison of different ratios of cefoperazone/sulbactam in patients with pyelonephritis
por: Jiang, Weizhong, et al.
Publicado: (2023)

Risk Factors for Cefoperazone/Sulbactam-Induced Coagulation Disorder
por: Miao, Wan, et al.
Publicado: (2023)

Acute localized exanthematous pustulosis caused by cefoperazone and sodium sulbactam
por: Qu, Yan-Jing, et al.
Publicado: (2016)

Glucose-Potentiated Amikacin Killing of Cefoperazone/Sulbactam Resistant Pseudomonas aeruginosa
por: Tang, Xi-kang, et al.
Publicado: (2022)

Clinical Outcomes and Adverse Effects in Septic Patients with Impaired Renal Function Who Received Different Dosages of Cefoperazone–Sulbactam
por: Tai, Chien-Hsiang, et al.
Publicado: (2022)

Comparison of Efficacy of Cefoperazone/Sulbactam and Imipenem/Cilastatin for Treatment of Acinetobacter Bacteremia
por: Choi, Jun Yong, et al.
Publicado: (2006)

Case report: Cefoperazone-sulbactam induced Kounis syndrome and cardiogenic shock
por: Ding, Peng, et al.
Publicado: (2022)

Evaluation of Piperacillin/Sulbactam, Piperacillin/Tazobactam and Cefoperazone/Sulbactam Dosages in Gram-Negative Bacterial Bloodstream Infections by Monte Carlo Simulation
por: Wang, Xueting, et al.
Publicado: (2023)

Comparison of antibiotic-associated diarrhea caused by cefoperazone/sulbactam or piperacillin/tazobactam in neurosurgery patients
por: Chen, Yue, et al.
Publicado: (2021)

Drug concentrations in the serum and cerebrospinal fluid of patients treated with cefoperazone/sulbactam after craniotomy
por: Wang, Qiang, et al.
Publicado: (2015)

A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infections
por: Xin, Xiaojuan, et al.
Publicado: (2013)

Cefoperazone and sulbactam-related eosinophilic peritonitis: a case report and literature review
por: Wang, Zi, et al.
Publicado: (2021)

Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature
por: Kogilathota Jagirdhar, Gowthami Sai, et al.
Publicado: (2023)

Combined PK/PD Index May Be a More Appropriate PK/PD Index for Cefoperazone/Sulbactam against Acinetobacter baumannii in Patients with Hospital-Acquired Pneumonia
por: Zhou, Yingjie, et al.
Publicado: (2022)

Fatal Vitamin K-Dependent Coagulopathy Associated with Cefoperazone/Sulbactam: A Case Report
por: Hu, Huan-rong
Publicado: (2019)

Cross-reactivity between piperacillin–tazobactam and cefoperazone–sulbactam in drug-induced immune thrombocytopenia
por: He, Xiaoyan, et al.
Publicado: (2023)

Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii
por: Niu, Tianshui, et al.
Publicado: (2019)

Development and validation of a nomogram for predicting cefoperazone/sulbactam-induced hypoprothrombinaemia in Hospitalized adult patients
por: Bai, Hehe, et al.
Publicado: (2023)

Repressed Central Carbon Metabolism and Its Effect on Related Metabolic Pathways in Cefoperazone/Sulbactam-Resistant Pseudomonas aeruginosa
por: Chen, Yue-tao, et al.
Publicado: (2022)

Cefoperazone/Sulbactam-Induced Abdominal Wall Hematoma and Upper Gastrointestinal Bleeding: A Case Report and Review of the Literature
por: Cai, ZhuYing, et al.
Publicado: (2016)

Imipenem-Cilastatin versus Sulbactam-Cefoperazone plus Amikacin in the Initial Treatment of Febrile Neutropenic Cancer Patients
por: ÖZYILKAN, Özgür, et al.
Publicado: (1999)

Case Report: Drug-Induced Immune Haemolytic Anaemia Caused by Cefoperazone-Tazobactam/ Sulbactam Combination Therapy
por: Wu, Yuanjun, et al.
Publicado: (2021)

Cefoperazone-sulbactam and ornidazole for Gardnerella vaginalis bloodstream infection after cesarean section: A case report
por: Mu, Yu, et al.
Publicado: (2022)

Risk-factor analysis and predictive-model development of acute kidney injury in inpatients administered cefoperazone-sulbactam sodium and mezlocillin-sulbactam sodium: a single-center retrospective study
por: Zhang, Ruiqiu, et al.
Publicado: (2023)

Nitrite Promotes ROS Production to Potentiate Cefoperazone-Sulbactam-Mediated Elimination to Lab-Evolved and Clinical-Evolved Pseudomonas aeruginosa
por: Kuang, Su-fang, et al.
Publicado: (2022)

Outcomes of Adjunctive Therapy with Intravenous Cefoperazone-Sulbactam for Ventilator-Associated Pneumonia Due to Carbapenem-Resistant Acinetobacter baumannii
por: Kanchanasuwan, Siripen, et al.
Publicado: (2021)

The Investigation on Nosocomial Infection of Acinetobacter baumannii and the Clinical Analysis of Sequential Therapy of Cefoperazone/Sulbactam Sodium for Intracranial Infection
por: Xiong, Zezhong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6r1lur2a2orodpebrp73s7vbpa